These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males. Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571 [TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers. Wong SL; Awni WM; Cavanaugh JH; el-Shourbagy T; Locke CS; Dubé LM Clin Pharmacokinet; 1995; 29 Suppl 2():9-21. PubMed ID: 8620676 [TBL] [Abstract][Full Text] [Related]
10. Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients. Lehnigk B; Rabe KF; Dent G; Herst RS; Carpentier PJ; Magnussen H Eur Respir J; 1998 Mar; 11(3):617-23. PubMed ID: 9596112 [TBL] [Abstract][Full Text] [Related]
11. The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects. Van Schoor J; Joos GF; Kips JC; Drajesk JF; Carpentier PJ; Pauwels RA Am J Respir Crit Care Med; 1997 Mar; 155(3):875-80. PubMed ID: 9117020 [TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics of zileuton in healthy young and elderly volunteers. Braeckman RA; Granneman GR; Locke CS; Machinist JM; Cavannaugh JH; Awni WM Clin Pharmacokinet; 1995; 29 Suppl 2():42-8. PubMed ID: 8620670 [TBL] [Abstract][Full Text] [Related]
14. Identification of the human liver cytochrome P450 enzymes involved in the in vitro metabolism of a novel 5-lipoxygenase inhibitor. Machinist JM; Mayer MD; Roberts EM; Surber BW; Rodrigues AD Drug Metab Dispos; 1998 Oct; 26(10):970-6. PubMed ID: 9763401 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the diurnal variation in the pharmacokinetics of zileuton in healthy volunteers. Awni WM; Locke C; Dube LM; Cavanaugh JH J Clin Pharmacol; 1997 May; 37(5):388-94. PubMed ID: 9156371 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis. Mohamed MF; Camp HS; Jiang P; Padley RJ; Asatryan A; Othman AA Clin Pharmacokinet; 2016 Dec; 55(12):1547-1558. PubMed ID: 27272171 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor. Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. Zhao RK; Cheng G; Tang J; Song J; Peng WX Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103 [TBL] [Abstract][Full Text] [Related]
19. The effect of food on the pharmacokinetics of zileuton. Awni WM; Cavanaugh JH; Witt G; Granneman GR; Dubé LM Clin Pharmacokinet; 1995; 29 Suppl 2():62-6. PubMed ID: 8620672 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety. Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]